Quantum Financial Advisors LLC Boosts Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Quantum Financial Advisors LLC has increased its stake in Eli Lilly and Company by 34.4%, now owning 1,489 shares valued at approximately $1.16 million.
• Eli Lilly recently reported quarterly earnings of $6.31 per share, exceeding analysts' expectations, with a revenue of $15.56 billion for the quarter.
• The company declared a quarterly dividend of $1.50 per share, representing an annualized dividend yield of 0.8%.

Quantum Financial Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 34.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,489 shares of the company's stock after purchasing an additional 381 shares during the quarter. Quantum Financial Advisors LLC's holdings in Eli Lilly and Company were worth $1,160,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Brighton Jones LLC raised its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after buying an additional 40 shares in the last quarter. Bank Pictet & Cie Europe AG raised its position in shares of Eli Lilly and Company by 4.1% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock valued at $49,993,000 after buying an additional 2,568 shares in the last quarter. Retirement Planning Group LLC raised its position in shares of Eli Lilly and Company by 5.2% in the 4th quarter. Retirement Planning Group LLC now owns 364 shares of the company's stock valued at $281,000 after buying an additional 18 shares in the last quarter. Finally, Pinney & Scofield Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $5,694,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Morgan Stanley reissued an "overweight" rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Finally, Cantor Fitzgerald reduced their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $939.61.

Eli Lilly and Company Stock Down 1.2%

Shares of Eli Lilly and Company stock traded down $8.79 during trading hours on Tuesday, reaching $746.16. The company's stock had a trading volume of 1,496,329 shares, compared to its average volume of 4,083,000. The stock's fifty day simple moving average is $737.49 and its two-hundred day simple moving average is $769.01. The company has a market capitalization of $706.21 billion, a P/E ratio of 48.77, a P/E/G ratio of 1.05 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $939.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.